And it’s on sale right now for as little as $25!
Coach Tom Allen and the No. 17 Indiana Hoosiers celebrated wildly after Saturday's monumental upset of Penn State. “Rutgers is a very different football team than it’s been in the past and it’s very obvious on film," Allen said.
US policymakers held another round of talks Monday on a new spending package to aid the virus-hit economy, but the negotiations have lost momentum, dimming hopes that an agreement can be reached before the November 3 election.
Community Health Systems, Inc. (NYSE: CYH) announced today that subsidiaries of the Company have completed the sale of two Texas hospitals – 231-bed Abilene Regional Medical Center in Abilene and 188-bed Brownwood Regional Medical Center in Brownwood and their associated assets – to subsidiaries of Hendrick Health System. The effective date of the transactions is October 27, 2020. With the divestitures completed, Community Health Systems affiliates continue to operate seven hospitals in Texas.
The predictive maintenance market in SAM is expected to grow from US$ 274. 62 million in 2019 to US$ 736. 89 million by 2027; it is estimated to grow at a CAGR of 13. 3% from 2020 to 2027. Improved asset management for every vertical is increasingly needed.New York, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "South America Predictive Maintenance Market Forecast to 2027 – COVID-19 Impact and Analysis – by Component, Deployment Type, Technique, and Industry" - https://www.reportlinker.com/p05978930/?utm_source=GNW Solution providers equipped with machine learning (ML) and artificial intelligence (AI) can collect and make meaningful insights into the vast amount of customer-related data as internet of things (IoT) generates a massive amount of data from connected devices.Moreover, to optimize various aspects of service delivery, such as quality assessment and predictive maintenance, AI can also be integrated with IoT devices without any human intervention.Inputs from actuators, sensors, and other control parameters in real-time would predict embryonic asset failures and help companies monitor and take prompt action in real-time, further driving the demand for predictive maintenance.The inputs from various control parameters help predict asset failures. This is among the other factors expected to positively influence the demand for predictive maintenance.The technology industry is one of the victims of COVID-19, and since the start of 2020, this industry has been reflecting the declining trend.With the imposition of lockdown across the SAM region, the trades have been witnessing shattering experience due to the unavailability of retailers, suppliers, online and authorized sales representatives in the market.The region is projected to register a swift decline in their supply of predictive maintenance components and have halted their manufacturing activities and subsequently disrupting the importing of parts and equipment.Based on industry, the manufacturing segment led the SAM predictive maintenance market in 2019.Traditionally, maintenance professionals used to combine both quantitative and qualitative techniques, to predict impending failures and mitigate downtime in their manufacturing plants.Predictive maintenance provides them with the potential to optimize maintenance tasks in real-time, maximizing their equipment’s useful life while avoiding operational disruption.For organizations producing products on a mass scale, predictive maintenance is an impressive way to reduce defects in products and eliminate waste.For those who provide parts and machinery, predictive maintenance is commonly used to set the technology for monitoring and inspecting the condition of the moving apparatus and motors.Productivity, power, state of health, and wear within are all effectively monitored.The growing need to maintain production equipment, such as industrial robots, machinery, elevators, and pumps, to reduce overall downtimes drives the adoption of predictive maintenance solutions and services in the manufacturing industry. The growing automation in the manufacturing sector, coupled with Industry 4.0, is expected to boost the demand for predictive maintenance to protect the high-end equipment from damage, which ultimately drives the SAM predictive maintenance market.The overall SAM predictive maintenance market size has been derived using both primary and secondary sources.To begin the research process, exhaustive secondary research has been conducted using internal and external sources to obtain qualitative and quantitative information related to the market.The process also serves the purpose of obtaining overview and forecast for the SAM predictive maintenance market with respect to all the segments pertaining to the region.Also, multiple primary interviews have been conducted with industry participants and commentators to validate the data, as well as to gain more analytical insights into the topic.The participants who typically take part in such a process include industry experts, such as VPs, business development managers, market intelligence managers, and national sales managers, along with external consultants, such as valuation experts, research analysts, and key opinion leaders specializing in the SAM predictive maintenance market. Key players operating in the SAM predictive maintenance market include Hitachi, Ltd.; IBM Corporation; Microsoft Corporation; PTC Inc.; Schneider Electric SE; SAS Institute Inc.; and General Electric Company.Read the full report: https://www.reportlinker.com/p05978930/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________CONTACT: Clare: email@example.com US: (339)-368-6001 Intl: +1 339-368-6001
Coming off an unusual bye week that included daily COVID-19 testing, a stay-safe directive and the addition of sack specialist Yannick Ngakoue, the Baltimore Ravens have turned their attention toward Sunday’s AFC North showdown with the unbeaten Pittsburgh Steelers. Baltimore's bye came a week earlier than scheduled after the pandemic forced the postponement of the Oct. 4 game between Pittsburgh and Tennessee to Sunday. The Steelers won to improve to 6-0 while the Ravens (5-1) wrapped up a mellow weekend in the area.
Immigration law firm Fragomen, Del Rey, Bernsen & Loewy has confirmed a data breach involving the personal information of current and former Google employees. The New York-based law firm provides companies with employment verification screening services to determine if employees are eligible and authorized to work in the United States.
At this time, for opening remarks and introductions, I would like to turn the call over to Vice President of Investor Relations Mr. Mark Kimbrough. With me this morning is our CEO, Sam Hazen; our CFO Bill Rutherfor; along with our CMO, Dr. Jon Perlin.
B&G Foods, Inc. (NYSE: BGS) announced today that it has entered into an agreement to acquire the iconic Crisco brand of oils and shortening from The J.M. Smucker Co. for approximately $550 million in cash, subject to a post-closing inventory adjustment. As part of the acquisition, B&G Foods is also acquiring a manufacturing facility and warehouse in Cincinnati, Ohio. B&G Foods expects the acquisition to close during the fourth quarter of 2020, subject to customary closing conditions, including the receipt of regulatory approvals.
Scorching deserts to green pastures: Jordan's diverse climateCountry encompasses hills, desert and the lowest point on Earth
Energy Transfer LP (NYSE: ET) today announced a quarterly cash distribution of $0.1525 per ET common unit ($0.61 on an annualized basis) for the third quarter ended September 30, 2020. The announced quarterly distribution will be paid on November 19, 2020 to unitholders of record as of the close of business on November 6, 2020.
Outdoor Advertising market will register an incremental spend of about USD 9 billion, growing at a CAGR of 3.96% during the five-year forecast period.
The Global Commercial Telematics Market will grow by USD 23.15 bn during 2020-2024
LYON, France and CAMBRIDGE, Mass., Oct. 26, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announced the appointment of Dr. Stewart Craig as its Chief Technical Officer (CTO) and member of the executive team. Dr. Craig brings 35 years of experience in the development, manufacturing, technical operations, quality systems and regulatory affairs for complex biologics and cell & gene therapies worldwide. “We are delighted to officially welcome Stewart to the ERYTECH team in his new role as CTO after working with the Company on a consultancy basis for the past year. It is paramount that we have such a seasoned leader driving our technology forward at this exciting juncture for the company,” said Gil Beyen, CEO of ERYTECH. “With our lead product candidate eryaspase nearing completion of two potentially pivotal clinical trials, Stewart’s extensive knowledge and first-hand experience in advancing the manufacturing and supply chain operations of complex therapeutics to commercial scale will be an invaluable asset in ensuring helping us achieve our global operational readiness.” For the past 25 years, Dr. Craig has held executive level positions designing, implementing and operating the CMC and GMP manufacturing infrastructure for various pioneering cell and gene therapy companies, including as Chief Manufacturing Officer of Orchard Therapeutics, SVP Technical Operations of Sangamo, EVP Manufacturing & Regulatory at Stemcells Inc., Chief Technology Officer at PCT Cell Therapy Services and Chief Operating Officer at Xcyte Therapies. Stewart also has extensive experience in the successful management of regulatory affairs for cell and gene therapy submissions in the US, Canada and Europe. Stewart holds a B.Sc. in Biochemistry and a Ph.D. in Physical Biochemistry from Newcastle University (U.K.). He is based in the United States, where he has been located since 1994. “With a transformative platform technology and three candidates in late stage clinical trials ongoing, ERYTECH is a leader in red blood cell-based cancer therapy,” stated Dr. Craig. “I’m thrilled to join ERYTECH’s management at this important stage of development. To be a part of this leadership team and accelerate the company’s programs to a commercially successful operation, is a sincere honor, having spent the last 12 months with the team and the technology”. About ERYTECH ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS® platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH’s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival. The Company’s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cells’ altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of first-line triple-negative breast cancer. An investigator-sponsored Phase 2 study in acute lymphoblastic leukemia is ongoing in the Nordic countries of Europe. ERYTECH produces its product candidates for treatment of patients in Europe at its GMP-approved manufacturing site in Lyon, France, and for patients in the United States at its GMP manufacturing site in Princeton, New Jersey, USA. ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes. For more information, please visit www.erytech.com Forward-looking information This press release contains forward-looking statements including but not limited to statements with respect to the clinical development plans for the Company’s product candidates and their commercial prospects. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”,“plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond ERYTECH's control. There can be no guarantees with respect to pipeline product candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. Therefore, actual results and timeline may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Further description of these risks, uncertainties and other risks can be found in the Company’s regulatory filings with the French Autorité des Marchés Financiers (AMF), the Company’s Securities and Exchange Commission (SEC) filings and reports, including in the Company’s 2019 Document d’Enregistrement Universel filed with the AMF on March 18, 2020, in the half-year report for the six-month period ended June 30, 2020 published on September 21, 2020 and in the Company’s Annual Report on Form 20-F filed with the SEC on March 18, 2020 and future filings and reports by the Company. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements. ERYTECH disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in ERYTECH’s expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by law. In addition, the COVID-19 pandemic and the associated containment efforts have had a serious adverse impact on the economy, the severity and duration of which are uncertain. Government stabilization efforts will only partially mitigate the consequences. The extent and duration of the impact on the Company’s business and operations is highly uncertain, and that impact includes effects on its clinical trial operations and supply chain. Factors that will influence the impact on the Company’s business and operations include the duration and extent of the pandemic, the extent of imposed or recommended containment and mitigation measures, and the general economic consequences of the pandemic. The pandemic could have a material adverse impact on the Company’s business, operations and financial results for an extended period of time. CONTACTS ERYTECH Eric SoyerCFO & COOLifeSci Advisors, LLCInvestor RelationsCorey Davis, Ph.D.NewCapMathilde Bohin / Louis-Victor DelouvrierInvestor relationsNicolas MerigeauMedia relations+33 4 78 74 44 38investors@ERYTECH.com+1 (212) 915 - 2577 firstname.lastname@example.org+33 1 44 71 94 94 ERYTECH@newcap.eu PDF available at: http://ml.globenewswire.com/Resource/Download/eb13760b-c74c-4e32-a0d6-86adba3ddc83
The cloud communications company, however, expects to post a loss of 8 cents to 11 cents per share for the current quarter. Analysts on average were expecting a profit of 2 cents. Excluding items, Twilio posted a profit of 4 cents per share for the third quarter, while analysts had expected a loss of 3 cents per share.
Saama and Gilead launch co-built Active Safety Analytics for Pharma (ASAP) to transform safety surveillance.
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Allergan plc.
To hear the NFL's last unbeaten team tell it, the Pittsburgh Steelers are perfect in record only. Well, the process needs some work after Pittsburgh allowed Titans to nearly erase a 20-point second-half deficit. “There’s a way that we like to play and there’s a lot of meat on that bone as coach likes to say,” Heyward said.
Javicia Leslie is the first Black actress to portray Batwoman for a live-action TV show or movie
The Tampa Bay Buccaneers are off to their best start in 10 years and betting on Antonio Brown to not derail a promising season. The suspended receiver who hasn’t caught a pass in the NFL in more than 13 months is reuniting with Tom Brady on an incentive-laden, one-year contract. Brown is expected to begin practicing with the first-place Bucs (5-2) on Wednesday.